- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00845936
Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics
Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study
Atypical antipsychotics (AA) are broadly used to treat a variety of psychiatric and neurological disorders in children and adolescents. Weight gain is a common side effect of these drugs. AA induced weight gain can be the cause of the metabolic syndrome which is a major health concern, as well as cancer and significant psychological disorders. Weight gain may also lead to low compliance with AAs.
A number of studies have been conducted in order to find a way to prevent, reduce or reverse AA induced weight gain in children and adolescents, but so far there is no commonly accepted treatment for the problem.
Metformin is an antihyperglycemic drug, approved by the FDA for treatment of type 2 diabetes in children older than 10 years of age. The drug usually does not cause hypoglycemia, even in high dosage. Contraindications include renal impairment, hepatic disease, a past history of lactic acidosis (of any cause), cardiac failure requiring pharmacological therapy, or chronic hypoxic lung disease. The drug also should be discontinued temporarily prior to the administration of intravenous contrast media and prior to any surgical procedure. The reported incidence of lactic acidosis during metformin treatment is less than 0.1 cases per 1000 patient-years, and the mortality risk is even lower.
Acute side effects of metformin, which occur in up to 20% of patients, include diarrhea, abdominal discomfort, nausea, metallic taste, and anorexia. These usually can be minimized by increasing the dosage of the drug slowly, when indicated, and taking it with meals. Intestinal absorption of vitamin B 12 and folate often is decreased during chronic metformin therapy, and calcium supplements reverse the effect of metformin on vitamin B12 absorption.
Three studies have studied the effect of metformin on weight gain secondary to use of AAs in adults and 3 other studies studied the effect of metformin in children and adolescents. Most of these studies have proved the drug to be efficient. No serious side effects have been demonstrated in any of these studies.
Objective- To assess the effect of metformin on body weight of children and adolescents treated by AAs.
Setting- recruitment and follow up would take place in the pediatric ward and outpatient clinic at the Ness- Tziona Mental Health Center.
Participants- 30 adolescents aged 12- 20 years old, treated with AAs, who are overweight as defined by more than 10% of what is expected according to age and height.
Importance of the Study
- Identify a medication capable of reducing or preventing weight gain by an AA agent.
- Identify an agent capable of improving compliance due to lower side-effect profile of AAs.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Pazit Leibovich, MD
- Phone Number: 972-9284065
- Email: pazit.leib@gmail.com
Study Locations
-
-
-
Beer Yaacov, Israel, 70350
- Beer-Yaacov MHC
-
Contact:
- Pazit Leibovich, MD
- Phone Number: 972-9284065
- Email: pazit.leib@gmail.com
-
Sub-Investigator:
- Pazit Leibovich, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12-20 year olds treated by atypical antipsychotics
- weight gain of more than 10% than expected for age
- Overweight of more than 10% than expected for age and height
Exclusion Criteria:
- Physical conditions requiring pharmacological treatment
- Changes in drug type or dosage 2 months before the trial, except for 25% changes in dosage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
850 mg of Metformin bid
|
Metformin 850 mg bid
|
Placebo Comparator: placebo
Tablets Identical to Metformin, bid
|
Metformin 850 mg bid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Weight loss
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
BMI, Weist circumstance, Blood pressure,Blood cholesterol,Fasting blood glucose and Insulin, Leptin levels. For safety- B12, Folate, lactate
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Metformin-38CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Induced Weight Gain
-
Response PharmaceuticalsCompletedDrug-induced Weight GainUnited States
-
Corcept TherapeuticsCompletedAntipsychotic-induced Weight GainUnited Kingdom
-
Nationwide Children's HospitalCompletedObesity | Weight Gain | Psychotropic Induced Weight GainUnited States
-
Western University, CanadaIowa State UniversityCompletedBirth Weight | Excessive Weight Gain in Pregnancy With Baby Delivered | Excessive Weight Gain in Pregnancy, First TrimesterCanada
-
Corcept TherapeuticsCompletedAntipsychotic-induced Weight Gain (AIWG)United States
-
Andalas UniversityNational Institute of Health Research and Development, Ministry of Health...CompletedBirth Weight | Pregnancy Weight GainIndonesia
-
University of PittsburghThe Obesity Society; Weight Watchers InternationalCompletedObesity | Weight Gain, Maternal | Postpartum Weight RetentionUnited States
-
Corcept TherapeuticsCompletedNon-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight GainUnited States
-
T.C. ORDU ÜNİVERSİTESİEge UniversityCompletedGestational Weight GainTurkey
-
University of HawaiiCompletedGestational Weight GainUnited States
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland